v3.26.3
SEGMENT AND ENTERPRISE-WIDE INFORMATION (Tables)
 6 Months Ended
Sep. 26, 2026
Segment Reporting [Abstract]  
Selected Information by Business Segment
Selected information by reportable segment is presented below:
Three Months EndedSix Months Ended
September 26, 2026September 27, 2025September 26, 2026September 27, 2025
(Dollars in Thousands)
Net revenues:
Apheresis$204,805 $181,818 $396,123 $363,554 
MedSurg152,954 145,497 301,016 285,155 
Total net revenues$357,759 $327,315 $697,139 $648,709 
Significant segment expenses and operating income:
Apheresis
Cost of goods sold$88,456 $79,967 $172,587 $155,832 
Selling, general and administrative47,303 38,265 91,567 78,145 
Research and development6,647 6,170 13,025 12,986 
Apheresis operating income$62,399 $57,416 $118,944 $116,591 
MedSurg
Cost of goods sold$47,673 $49,318 $98,041 $99,534 
Selling, general and administrative63,770 57,966 128,930 120,289 
Research and development9,854 8,352 19,674 17,094 
MedSurg operating income$31,657 $29,861 $54,371 $48,238 
Corporate and unallocated expenses
Amortization of acquired assets$(10,403)$(13,237)$(20,607)$(27,065)
Integration and transaction costs(2,551)(1,520)(5,317)(4,202)
Restructuring and restructuring related costs215 (258)(2,043)(1,582)
Digital transformation costs(5,405)(5,054)(11,568)(10,409)
Other(1)
(792)(8,717)(1,202)(9,208)
Operating income75,120 58,491 132,578 112,363 
Interest and other expense, net(12,261)(7,206)(22,145)(15,909)
Income before provision for income taxes$62,859 $51,285 $110,433 $96,454 
__________
(1)    Comprised of intangible asset impairments, litigation-related charges and remeasurement of contingent consideration for the three and six months ended September 26, 2026 and September 27, 2025
Schedule of Revenues by Business Unit and Geographic Regions
Net revenues by business unit are as follows:
Three Months EndedSix Months Ended
September 26, 2026September 27, 2025September 26, 2026September 27, 2025
(Dollars in Thousands)
Apheresis
Plasma$162,584 $139,614 $318,108 $284,688 
Other42,221 42,204 78,015 78,866 
Apheresis net revenues$204,805 $181,818 $396,123 $363,554 
MedSurg
Interventional Technologies$60,508 $59,073 $120,450 $117,556 
Blood Management Technologies92,446 86,424 180,566 167,599 
MedSurg net revenues$152,954 $145,497 $301,016 $285,155 
Total net revenues$357,759 $327,315 $697,139 $648,709 
Depreciation and amortization, excluding impairment charges, by business unit are as follows:
Three Months EndedSix Months Ended
September 26, 2026September 27, 2025September 26, 2026September 27, 2025
(Dollars in Thousands)
Apheresis$13,978 $13,882 $27,609 $27,794 
MedSurg13,782 14,373 27,262 29,219 
Total depreciation and amortization (excluding impairment charges)$27,760 $28,255 $54,871 $57,013 
Long-lived assets, comprised of property, plant and equipment, by business unit are as follows:
September 26, 2026March 28, 2026
(Dollars in Thousands)
Apheresis$246,068 $246,042 
MedSurg61,853 59,719 
Total long-lived assets$307,921 $305,761 
Long-lived assets, comprised of property, plant and equipment, by operating regions are as follows:
September 26, 2026March 28, 2026
(Dollars in Thousands)
United States$228,410 $224,699 
Japan817 916 
Europe31,784 32,080 
Rest of Asia29,712 30,833 
Other17,198 17,233 
Total long-lived assets$307,921 $305,761 
Net revenues by operating regions are as follows:
Three Months EndedSix Months Ended
September 26, 2026September 27, 2025September 26, 2026September 27, 2025
(Dollars in Thousands)
United States$267,807 $240,089 $525,651 $482,493 
Japan16,092 18,011 28,950 31,659 
Europe46,611 42,965 92,140 83,847 
Rest of Asia23,663 22,567 43,826 44,215 
Other3,586 3,683 6,572 6,495 
Total net revenues$357,759 $327,315 $697,139 $648,709